RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q4 2025 investor letter. A copy of the letter can be downloaded here. The US stock market delivered modest gains in the quarter with the S&P 500 index (“S&P”) and the Russell 1000 Growth index (“RLG”) returning 2.6% and 1.1%, respectively. The Fund appreciated by 1.4% during the same period. For the full year, the Fund was up 13.3% vs. 17.4% and 18.6% gains, respectively, for the indexes. The performance in the Russell 1000 Growth Index was uneven. Market leadership remains concentrated, but underlying divergence has deepened. Investors preferred companies with durable earnings and progress in monetizing growth, especially in health care and parts of the AI value chain. The Fund is optimistic that its portfolio consists of attractively valued companies benefiting from strong growth trends and expected to generate significant cash flow. Please review the Fund’s top five holdings to gain insights into their key selections for 2025.
In its fourth-quarter 2025 investor letter, RiverPark Large Growth Fund highlighted Eli Lilly and Company (NYSE:LLY). Eli Lilly and Company (NYSE:LLY) is a leading pharmaceutical company headquartered in Indianapolis, Indiana that develops, manufactures, and markets human pharmaceutical products. On March 24, 2026, Eli Lilly and Company (NYSE:LLY) stock closed at $903.02 per share. One-month return of Eli Lilly and Company (NYSE:LLY) was -7.08%, and its shares gained 13.07% over the past 52 weeks. Eli Lilly and Company (NYSE:LLY) has a market capitalization of $808.22 billion.
RiverPark Large Growth Fund stated the following regarding Eli Lilly and Company (NYSE:LLY) in its fourth quarter 2025 investor letter:
“Eli Lilly and Company (NYSE:LLY): Eli Lilly shares were a top performer in 4Q25 after delivering strong Q3 2025 earnings in October. Revenue rose 54% year-over-year to $17.6 billion, and adjusted EPS of $7.02 beat consensus of $6.02. Growth was driven by its GLP-1 franchises, Mounjaro and Zepbound, where sales more than doubled year-over-year, alongside strength in other therapeutic areas. Management raised full-year guidance for both revenue and earnings, reinforcing investor confidence in the company’s growth outlook.
We believe Lilly remains one of the highest-quality growth franchises in global healthcare. Its leadership in diabetes, obesity, and neuroscience provides durable competitive advantages and a robust innovation pipeline. With demand for GLP-1 treatments continuing to outpace supply and additional indications on the horizon, Lilly is well positioned to deliver sustained revenue and cash-flow growth over the coming decade.”
Eli Lilly and Company (NYSE:LLY) ranks 16th on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 137 hedge fund portfolios held Eli Lilly and Company (NYSE:LLY) at the end of the fourth quarter, up from 114 in the previous quarter. Eli Lilly and Company (NYSE:LLY) achieved impressive results in 2025, with revenue increasing by 45% to $65.2 billion, and fourth-quarter revenue growing by 43%. While we acknowledge the risk and potential of Eli Lilly and Company (NYSE:LLY) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Eli Lilly and Company (NYSE:LLY) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Eli Lilly and Company (NYSE:LLY) and shared a list of high profit margin stocks to buy according to hedge funds. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
